Cargando…

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts

The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of Alzheimer’s disease (AD) dementia has been controversial. The main objective of this study was to compare Aβ42 and tau levels measured by the ultra-sensitive immunomagnetic reduction (IMR) assays in plasma samples c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lue, Lih-Fen, Sabbagh, Marwan N., Chiu, Ming-Jang, Jing, Naomi, Snyder, Noelle L., Schmitz, Christopher, Guerra, Andre, Belden, Christine M., Chen, Ta-Fu, Yang, Che-Chuan, Yang, Shieh-Yueh, Walker, Douglas G., Chen, Kewei, Reiman, Eric M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522888/
https://www.ncbi.nlm.nih.gov/pubmed/28790911
http://dx.doi.org/10.3389/fnagi.2017.00226
_version_ 1783252239494676480
author Lue, Lih-Fen
Sabbagh, Marwan N.
Chiu, Ming-Jang
Jing, Naomi
Snyder, Noelle L.
Schmitz, Christopher
Guerra, Andre
Belden, Christine M.
Chen, Ta-Fu
Yang, Che-Chuan
Yang, Shieh-Yueh
Walker, Douglas G.
Chen, Kewei
Reiman, Eric M.
author_facet Lue, Lih-Fen
Sabbagh, Marwan N.
Chiu, Ming-Jang
Jing, Naomi
Snyder, Noelle L.
Schmitz, Christopher
Guerra, Andre
Belden, Christine M.
Chen, Ta-Fu
Yang, Che-Chuan
Yang, Shieh-Yueh
Walker, Douglas G.
Chen, Kewei
Reiman, Eric M.
author_sort Lue, Lih-Fen
collection PubMed
description The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of Alzheimer’s disease (AD) dementia has been controversial. The main objective of this study was to compare Aβ42 and tau levels measured by the ultra-sensitive immunomagnetic reduction (IMR) assays in plasma samples collected at the Banner Sun Health Institute (BSHRI) (United States) with those from the National Taiwan University Hospital (NTUH) (Taiwan). Significant increase in tau levels were detected in AD subjects from both cohorts, while Aβ42 levels were increased only in the NTUH cohort. A regression model incorporating age showed that tau levels identified probable ADs with 81 and 96% accuracy in the BSHRI and NTUH cohorts, respectively, while computed products of Aβ42 and tau increased the accuracy to 84% in the BSHRI cohorts. Using 382.68 (pg/ml)(2) as the cut-off value, the product achieved 92% accuracy in identifying AD in the combined cohorts. Overall findings support that plasma Aβ42 and tau assayed by IMR technology can be used to assist in the clinical diagnosis of AD.
format Online
Article
Text
id pubmed-5522888
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55228882017-08-08 Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts Lue, Lih-Fen Sabbagh, Marwan N. Chiu, Ming-Jang Jing, Naomi Snyder, Noelle L. Schmitz, Christopher Guerra, Andre Belden, Christine M. Chen, Ta-Fu Yang, Che-Chuan Yang, Shieh-Yueh Walker, Douglas G. Chen, Kewei Reiman, Eric M. Front Aging Neurosci Neuroscience The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of Alzheimer’s disease (AD) dementia has been controversial. The main objective of this study was to compare Aβ42 and tau levels measured by the ultra-sensitive immunomagnetic reduction (IMR) assays in plasma samples collected at the Banner Sun Health Institute (BSHRI) (United States) with those from the National Taiwan University Hospital (NTUH) (Taiwan). Significant increase in tau levels were detected in AD subjects from both cohorts, while Aβ42 levels were increased only in the NTUH cohort. A regression model incorporating age showed that tau levels identified probable ADs with 81 and 96% accuracy in the BSHRI and NTUH cohorts, respectively, while computed products of Aβ42 and tau increased the accuracy to 84% in the BSHRI cohorts. Using 382.68 (pg/ml)(2) as the cut-off value, the product achieved 92% accuracy in identifying AD in the combined cohorts. Overall findings support that plasma Aβ42 and tau assayed by IMR technology can be used to assist in the clinical diagnosis of AD. Frontiers Media S.A. 2017-07-24 /pmc/articles/PMC5522888/ /pubmed/28790911 http://dx.doi.org/10.3389/fnagi.2017.00226 Text en Copyright © 2017 Lue, Sabbagh, Chiu, Jing, Snyder, Schmitz, Guerra, Belden, Chen, Yang, Yang, Walker, Chen and Reiman. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Lue, Lih-Fen
Sabbagh, Marwan N.
Chiu, Ming-Jang
Jing, Naomi
Snyder, Noelle L.
Schmitz, Christopher
Guerra, Andre
Belden, Christine M.
Chen, Ta-Fu
Yang, Che-Chuan
Yang, Shieh-Yueh
Walker, Douglas G.
Chen, Kewei
Reiman, Eric M.
Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
title Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
title_full Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
title_fullStr Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
title_full_unstemmed Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
title_short Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
title_sort plasma levels of aβ42 and tau identified probable alzheimer’s dementia: findings in two cohorts
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522888/
https://www.ncbi.nlm.nih.gov/pubmed/28790911
http://dx.doi.org/10.3389/fnagi.2017.00226
work_keys_str_mv AT luelihfen plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT sabbaghmarwann plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT chiumingjang plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT jingnaomi plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT snydernoellel plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT schmitzchristopher plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT guerraandre plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT beldenchristinem plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT chentafu plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT yangchechuan plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT yangshiehyueh plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT walkerdouglasg plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT chenkewei plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts
AT reimanericm plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts